On February 18th, Polymed announced that it has granted Photys Therapeutics an exclusive license for the development, production, and commercialization of HPB-143, a protein degrading agent targeting IRAK4, worldwide (excluding Greater China and Southeast Asia). Multi domain Biotech receives corresponding down payments, recent payments, milestone payments for clinical development and drug launch, sales commissions and milestone payments, as well as partial equity in Photys.

 

 

 

It is reported that Duoyu Biotechnology is committed to developing "best in class" new drug research and development projects, especially focusing on related fields such as cancer, autoimmunity, and inflammation. In the press release, it was pointed out that the developed HPB-143 has higher oral bioavailability; Weak inhibition of hERG ion channel in the heart, with higher potential for human cardiac safety; And it has demonstrated lower effective doses and better efficacy in various mouse disease models.

 

 

 

On February 16th, Beihai Biotechnology announced a strategic partnership with Zydus Lifesciences and awarded them the new drug BEIZARY ® Exclusive commercial rights in the US market. It is reported that BH009 (trade name: BEIZRAY ®) It is mainly used for the treatment of breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, prostate cancer and gastric cancer.

 

 

 

It is reported that in clinical trials, BEIZARY can reduce the specific blood toxicity of docetaxel, overall improve the clinical benefit risk ratio of the drug, and provide better treatment options for advanced solid tumor patients.

 

 

 

According to the agreement, Beihai Biotechnology will be responsible for the production and supply of BEIBRAY, while Zydus Pharmaceuticals (USA), a subsidiary of Zydus in the United States, will be responsible for the commercialization of the product in the United States. Beihai Biotechnology will receive a down payment of $15 million (to be paid after the agreement is signed) and $10 million (to be paid after the first product delivery), as well as multiple sales milestone payments and high double-digit profit sharing.

 

 

 

On January 22nd, Lepu Biotechnology announced that it has reached a global exclusive licensing agreement with ArriVent BioPharma for the antibody conjugated drug (ADC) MRG007 for gastrointestinal cancer.

 

 

 

According to the agreement, Lepu Bio grants ArriVent an exclusive global license to develop, manufacture and commercialize MRG007 outside Greater China (including Chinese Mainland, Hong Kong, Macao and Taiwan, China). Lepu Biotech will receive a total of $47 million in one-time down payments and recent milestone payments, as well as up to $1.16 billion in milestone payments for development, registration, and sales, and tiered royalties based on net sales outside of Greater China.

 

 

 

On January 13th, Xiansheng Zaiming, an innovative anti-tumor drug company under Xiansheng Pharmaceutical, announced that it has reached a development license selection agreement with global pharmaceutical company AbbVie for its multiple myeloma (MM) candidate drug SIM0500, which is undergoing phase I clinical research in China and the United States.

 

 

 

SIM0500 is a humanized GPRC5D-BCMA-CD3 trispecific antibody. At present, the drug has undergone phase I clinical trials for multiple myeloma (MM) in both China and the United States, and was granted fast track status by the US Food and Drug Administration (FDA) in April 2024. According to the terms of the agreement, Xiansheng Zaiming will receive a down payment from AbbVie, as well as up to $1.055 billion in selective equity payments and milestone payments.

 

 

 

……

 

 

 

According to incomplete statistics, as of February 16th, there were 11 records of domestic innovative drug license out transactions, with a total amount exceeding 10 billion US dollars. Among them, there are multiple potential transactions with an estimated value of over 1 billion US dollars authorized to external parties, such as Xinda Biotechnology, Yingen Biotechnology, Xiansheng Pharmaceutical, and Lepu Biotechnology.

 

 

 

In this regard, the industry continues to be optimistic about the innovative drug market going global by 2025. Companies with differentiated innovation capabilities and potential for going global in the future are expected to see sustained growth in overseas commercialization revenue.